前列腺素类及其中间体
序号 | Product name | CAS number | Remarks |
1 | Bimatoprost 比马前列素 | 155206-00-1 | DMF 2016.Q4 |
2 | Latanoprost 拉坦前列腺素 | 130209-82-4 | DMF 2016.Q4 |
3 | Latanoprostene bunod 拉坦衍生物 | 860005-21-6 | DMF 2016.Q4 |
4 | Isopropyl Unoprostone 乌诺前列酮异丙酯 | 120373-24-2 | DMF 2017.Q1 |
5 | Travoprost 曲沃前列素 | 157283-68-6 | DMF 2016.Q4 |
6 | Lubiprostone 鲁比前列酮 | 333963-40-9 | DMF 2016.Q2 |
7 | Treprostinil sodium 曲前列素 | 289480-64-4 81846-19-7 (acid) | DMF 2016.Q4 |
8 | Iloprost 伊洛前列素 | 78919-13-8 | DMF 2017.Q4 |
9 | Misoprostol 米索前列醇 | 59122-46-2 | DMF 2016.Q1 |
10 | Tafluprost 他氟前列素 | 209860-87-7 | DMF 2016.Q4 |
11 | Dinoprostone (Prostaglandin E2) 地诺前列酮 (前列腺素E2) | 333963-40-9 363-24-6 | DMF 2017.Q1 |
12 | Alprostadil (ProstaglandinE1) 前列地尔(前列腺素E1) | 745-65-3 | R&D |
13 | Limaprost 利马前列素 | 74397-12-9 | R&D |
14 | Beraprost sodium 贝前列素 | 88475-69-8 88430-50-6 (acid) | R&D |
15 | Tiaprost 噻前列素 | 71116-82-0 | R&D |
16 | Dinoprost tromethamine 地诺前列素氨丁三醇 | 38562-01-5 (Dinoprost 551-11-1) | R&D |
17 | Epoprostenol sodium 依前列醇钠 | 61849-14-7 | R&D |
18 | Carboprost Tromethamine 卡前列素氨丁三醇 | 58551-69-2 | R&D |
19 | Etiproston 依替前列通 | 59619-81-7 | R&D |
20 | D-Cloprostenol Sodium D-氯前列烯醇钠 | 62561-03-9 | R&D |
21 | D-Cloprostenol D-氯前列烯醇 | 54276-22-1 | R&D |
22 | Trifluoromethyl Dechloro Ethylcloprostenolamide | 1005193-64-5 | R&D |
23 | (-)COD (-)-Corey Lactone Diol Purity: ≥99.0 % | 32233-40-2 | Prostaglandin Intermediates |
24 | (+)COD (+)-Corey Lactone Diol Purity: ≥99.0 % | 70764-05-7 | |
25 | BCOD (-)-Corey Lactone Benzoate Purity: ≥99.0 % | 39746-00-4 | |
26 | BPCOD (-)-Corey Lactone p-Phenyl Benzoate Purity: ≥99.0 % | 31752-99-5 | |
27 | TPPB (4-carboxybutyl)triphenylphosphonium bromide Purity: ≥99.0 % | 17814-85-6 | |
28 | AL-T [1R-(1a,2b,3a,5a)]-5-hydroxy-2-[(1-methoxy -1-methylethoxy)methyl]-3- [(tetrahydro-2H-pyran-2-yl)oxy] cyclopentaneheptanoic acid methyl ester Purity: ≥98.0 % | 69810-10-2 | Alprostadil Intermediates |
29 | BMP Dimethyl(2-oxo-4-phenylbutyl)phosphonate Purity: ≥94.0 % | 41162-19-0 | Bimatoprost & Latanoprost Intermediates |
30 | BP-2 (3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-5-phenyl-1 -pentenyl]-2H-cyclopenta[b]furan-2-one Purity: ≥99.0 % | 41639-74-1 | |
31 | LT-DI (3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(3R)-3-hydroxy-5-phenylpentyl] -2H-cyclopenta[b]furan-2-one Purity: ≥99.0 % | 145667-75-0 | |
32 | BM-BPH [1,1'-Biphenyl]-4-carboxylic acid, (3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]- 2-oxo-2H-cyclopenta[b]furan-5-yl ester Purity: ≥99.0 % | 41639-73-0 | |
| BM-BH (3aR,4R,5R,6aS)-5-(benzoyloxy)hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan- 2-one Purity: ≥99.0 % | 55444-68-3 | Bimatoprost & Latanoprost Intermediates |
34 | LT-TRI (3aR, 4R,5R,6aS)-hexahydro-4-[(3R)-3- hydroxy-5-phenylpentyl]-2H-cyclopenta[b]furan-2,5-diol Purity: ≥99.0 % | 352276-28-9 | |
35 | LT-Acid (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoic acid Purity: ≥98.0 % | 41639-83-2 | |
36 | LT-BPK [1,1'-Biphenyl]-4-carboxylic acid (3aR,4R, 5R,6aS)-hexahydro-2-oxo- 4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-5-yl ester Purity: ≥99.0 % | 41639-72-9 | |
37 | LT-BK (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one Purity: ≥99.0 % | 55076-60-3 | |
38 | CL-BK 5-(benzoyloxy)-4-[4-(3-chlorophenoxy)-3-oxo-1-butenyl]hexahydro-,[3aR-[3aa,4a (E),5b,6aa]]-2H-cyclopenta[b] furan-2-one Purity: ≥99.0 % | 178454-81-4 | Cloprostenol Intermediates |
39 | CL-BPK [1,1'-Biphenyl]-4-carboxylic acid [3a,4(E), 6a]-4-[4-(3-chlorophenoxy)- 3-oxo-1-butenyl]hexahydro-2-oxo-2H-cyclopenta[b]furan-5-yl ester Purity: ≥99.0 % | 54324-79-7 | |
40 | CL-BPH [3aR-[3a,4(1E,3R*),5,6a]]-[1,1'-Biphenyl]-4-carboxylic acid, 4-[4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-hexahydro-2-oxo-2H-cyclopenta[b]furan-5-yl ester Purity: ≥99.0 % |
54713-44-9
| |
41 | CL-DI (3aR,4R,5R,6aS)-4-[(1E,3R)-4- (3- chlorophenoxy)-3-hydroxy-1-buten-1-yl]hexahydro-5-hydroxy-2H-Cyclopenta[b]furan-2-one Purity: ≥99.0 % | 53906-54-0 | Cloprostenol Intermediates |
42 | CLP Dimethyl[2-oxo-3-(3-chloro-phenoxy)- propyl]phosphonate Purity: ≥99.0 % | 40665-94-9 | |
43 | DL-CP-2 (3aR,4R,5R,6aS)-4-[(1E)-4-(3-chloro phenoxy)-3-hydroxy-1-buten-1-yl] hexahydro-5-hydroxy-2H-cyclopenta[b] furan-2-one Purity: ≥99.0 % | 652152-39-1 | |
44 | DN-BPK [1,1'-Biphenyl]-4-carboxylic acid (3aR,4R, 5R, 6aS)-hexahydro-2-oxo- 4-[(1E)-3-oxo-1-octenyl]-2H-cyclopenta[b]furan-5-yl ester Purity: ≥99.0 % | 31753-00-1 | Dinoprostone Intermediates |
45 | DN-BK (3aR,4R,5R,6aS)-2-oxo-4-((E)-3-oxooct-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-5-yl benzoate Purity: ≥99.0 % | 40834-86-4 | |
46 | DN-BT (3aR,4R,5R,6aS)-5-(benzoyloxy)-4-[(1E, 3S)-3-[[(1,1-dimethylethyl) dimethylsilyl]oxy]-1-octen-1-yl]hexahydro-2H-cyclopenta[b]furan-2-one Purity: ≥99.0 % | 587869-81-6 | |
47 | DNP Dimethyl (2-oxoheptyl)phosphonate Purity: ≥92.0 % | 36969-89-8 | |
48 | DN-BPH [1,1'-Biphenyl]-4-carboxylic acid (3aR, 4R,5R,6aS)-hexahydro-4-[(1E,3S)-3- hydroxy-1-octen-1-yl]-2-oxo-2H- cyclopenta[b]furan-5-yl ester Purity: ≥98.0 % |
51014-26-7
| |
49 | DN-DI (Corey PG-Lactone Diol) (3aR,4R,5R,6aS)-5-hydroxy-4-((S,E)-3-hydroxyoct-1-en-1-yl)hexahydro-2H- cyclopenta[b]furan-2-one Purity: ≥98.0 % | 26054-67-1 | |
50 | LB-BPK [1,1'-Biphenyl]-4-carboxylic acid [3aR- [3aa, 4a(E),5b,6aa]]-4-(4,4-difluoro- 3-oxo-1-octenyl)hexahydro-2-oxo-2H- cyclopenta[b]furan-5-ylester Purity: ≥98.0 % | 118583-35-0 | Lubiprostone Intermediates |
51 | LBP Dimethyl(3,3-difluoro-2-oxoheptyl) phosphonate Purity: ≥97.0 % | 50889-46-8 | |
52 | IL-THTB [3aS-(3aa,4a,5b,6aa)]-4-[[[(tert-Butyl) dimethylsilyl]oxy]methyl]-5-[(tetrahydro-2H-pyran-2-yl)oxy]hexahydro-2(1H)- pentalenone Purity: ≥95.0 % | 112168-22-6 | Iloprost Intermediates |
53 | TF-DI (3aR,4R,5R,6aS)-4-[(1E)-3,3-difluoro- 4-phenoxy-1-buten-1-yl]hexahydro-2H- cyclopenta[b]furan-2,5-diol Purity: ≥98.0 % | 209861-02-9 | Tafluprost Intermediates |
54 | TF-HF (3aR,4R,5R,6aS)-4-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]hexahydro-5- hydroxy-2H-Cyclopenta[b]furan-2-one Purity: ≥98.0 % | 209861-01-8 | |
55 | TF-BF (3aR,4R,5R,6aS)-5-(benzoyloxy)-4-[(1E)- 3,3-difluoro-4-phenoxy-1-buten- 1-yl]hexahydro-2H-Cyclopenta[b]furan-2-one Purity: ≥99.0 % | 209861-00-7 | |
56 | TF-BPF (3aR,4R,5R,6aS)-5-(p-phenylbenzoyloxy)-4-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]hexahydro-2H-cyclopenta[b]furan-2-one Purity: ≥99.0 % | ||
57 | TI-BPK [3aR- [3a,4(E),5,6a]]-[1,1'-Biphenyl]-4- carboxylic acid, hexahydro-2-oxo-4-[3- oxo-4-(3-thienyloxy)-1-butenyl]-2H- cyclopenta[b]furan-5-yl ester Purity: ≥98.0 % |
63150-91-4
| Tiaprost Intermediates |
58 | TIP Dimethyl [2-oxo-3-(3-thienyloxy)- propyl] phosphonate Purity: ≥93.0 % | 62401-58-5 | |
59 | TV-BPK [1,1'-Biphenyl]-4-carboxylicacid (3aR,4R, 5R,6aS)-hexahydro-2-oxo-4- [(1E)-3-oxo -4-[3-(trifluoromethyl) phenoxy]-1-buten-1-yl]-2H-cyclopenta[b]furan-5-yl ester Purity: ≥99.0 % | 54142-64-2 | Travoprost Intermediates |
60 | TV-BK (3aR,4R,5R,6aS)-5-(Benzoyloxy) hexahydro-4-[(1E)-3-oxo-4-[3- (trifluoromethyl)phenoxy]-1-buten-1-yl]- 2H-cyclopenta[b]furan-2-one Purity: ≥99.0 % | 208111-98-2 | |
61 | TVP Dimethyl[2-Oxo-3-(3-trifluoromethyl- phenoxy)-propyl]phosphonate Purity: ≥93.0 % | 54094-19-8 | |
62 | TV-DI (3aR,4R,5R,6aS)-Hexahydro-5- hydroxy-4-[(1E,3R)-3-hydroxy-4-(3- trifluoromethyl)phenoxy-1-butenyl]-2H- cyclopenta[b]furan-2-one Purity: ≥99.0 % | 53872-60-9 | |
63 | TV-TRI (3aR,4R,5R,6aS)-hexahydro-4-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]-2H-cyclopenta[b]furan-2,5- diol Purity: ≥99.0% | 1204185-88-5 | |
64 | ETP Dimethyl (3-phenoxy-2-oxopropyl) phosphonate Purity: ≥95.0 % | 40665-68-7 | Etiproston & Tafluprost Intermediates |
65 | ENT-HT (1R,3R,4S)-4-(tert-butyldimethylsilyloxy)-3-((tert-butyldimethylsilyloxy)methyl)-2-methylenecyclopentanol Purity: ≥98.0 % | 701278-56-0 | Entecavir Intermediates |
66 | EN-2 [1,1'-Biphenyl]-4-carboxylic acid hexahydro-2-oxo-4-[2-[2-(phenoxy methyl)-1,3-dioxolan-2-yl]ethenyl]-2H- cyclopenta[b]furan-5-yl ester Purity: ≥98.0 % | 118392-79-3 | Enprostone Intermediates |
67 | EN-CPN 16-phenoxy tetranor PGF2α cyclopropyl methyl amide Purity: ≥98.0 % | 1138395-09-1 |
* Remark: Patented products available for research and development use ONLY as permitted under CFR 35 see 271 (e) (1)
.